The RNF41 protein could be another remedial objective in the battle against two ongoing liver illnesses: cirrhosis and liver aggravation. This is the decision of a review distributed in the journal Science Translational Medication, driven by specialist Pedro Melgar-Lesmes, from the Division of Biomedicine at the Workforce of Medication and Wellbeing Studies of the College of Barcelona. This study could prompt the development of medications that improve the development of RNF41 protein in macrophages, guarded cells of the safe framework that assume a fundamental role in the reaction to liver harm and in the movement of persistent liver sickness. Melgar-Lesmes